Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 20, 2015 9:58 PM ET


Company Overview of Cubist Pharmaceuticals Inc.

Executive Profile

Steven C. Gilman Ph.D.

Chief Scientific Officer and Executive Vice President of Research & Development, Cubist Pharmaceuticals Inc.
AgeTotal Calculated CompensationThis person is connected to 3 Board Members in 3 different organizations across 5 different industries.

See Board Relationships
As of Fiscal Year 2013


Dr. Steven C. Gilman, also known as Steve, Ph.D., has been the Chief Scientific Officer at Cubist Pharmaceuticals Inc. since February 2008, and has been its Executive Vice President of Research & Development since September 2010. Dr. Gilman has more than 25 years of drug research and development experience. He served as a Senior Vice President of Discovery & Non Clinical Development at Cubist Pharmaceuticals Inc. since February 2008. He served as the Chairman of the ...

Corporate Headquarters

65 Hayden Avenue
Lexington, Massachusetts 02421

United States

Phone: 781-860-8660
Fax: --

Board Members Memberships

Former Chairman and Chief Executive Officer
Director, Member of Audit Committee and Member of Nominating & Corporate Governance Committee


Pennsylvania State University
Pennsylvania State University
Miami University

Other Affiliations

Annual Compensation

Total Annual Compensation$475,000

Stocks Options

Restricted Stock Awards$649,958
All Other Compensation$16,946
Exercised Options$30,125
Exercised Options Value$935,104
Exercisable Options$216,659
Exercisable Options Value$8,828,983
Unexercisable Options$127,317
Unexercisable Options Value$3,984,687
Total Value of Options$13,748,774
Total Number of Options$374,101

Total Compensation

Total Annual Cash Compensation$810,006
Total Short Term Compensation$475,000
Other Long Term Compensation$666,904
Total Calculated Compensation$2,109,958

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cubist Pharmaceuticals Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at